Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 10 studies | 20% ± 4% | |
lung | 10 studies | 22% ± 3% | |
brain | 9 studies | 33% ± 16% | |
heart | 5 studies | 19% ± 3% | |
eye | 4 studies | 27% ± 9% | |
liver | 4 studies | 30% ± 14% | |
adipose | 4 studies | 28% ± 14% | |
bone marrow | 3 studies | 19% ± 4% | |
kidney | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 4023.94 | 180 / 180 | 100% | 48.56 | 430 / 430 |
lung | 100% | 4579.16 | 577 / 578 | 100% | 54.44 | 1155 / 1155 |
skin | 100% | 4434.65 | 1805 / 1809 | 100% | 68.31 | 472 / 472 |
intestine | 100% | 5246.22 | 965 / 966 | 100% | 57.68 | 526 / 527 |
breast | 100% | 6186.57 | 459 / 459 | 100% | 82.56 | 1114 / 1118 |
uterus | 100% | 6381.38 | 170 / 170 | 100% | 60.70 | 457 / 459 |
esophagus | 100% | 5236.38 | 1445 / 1445 | 99% | 50.34 | 182 / 183 |
thymus | 100% | 3336.09 | 651 / 653 | 100% | 52.42 | 602 / 605 |
bladder | 100% | 5529.33 | 21 / 21 | 99% | 54.84 | 498 / 504 |
prostate | 100% | 3188.42 | 244 / 245 | 99% | 40.82 | 495 / 502 |
pancreas | 98% | 2534.15 | 322 / 328 | 99% | 61.97 | 177 / 178 |
stomach | 97% | 3104.14 | 349 / 359 | 100% | 60.15 | 286 / 286 |
kidney | 99% | 2740.71 | 88 / 89 | 98% | 66.02 | 885 / 901 |
adrenal gland | 98% | 2427.62 | 252 / 258 | 97% | 36.27 | 223 / 230 |
brain | 91% | 1520.10 | 2392 / 2642 | 100% | 63.46 | 705 / 705 |
liver | 73% | 1171.74 | 164 / 226 | 97% | 33.78 | 393 / 406 |
adipose | 100% | 7183.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 11083.01 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 58.61 | 29 / 29 |
spleen | 100% | 3205.55 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 51.08 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.09 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 32.97 | 79 / 80 |
peripheral blood | 98% | 3080.07 | 911 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 2737.03 | 834 / 861 | 0% | 0 | 0 / 0 |
muscle | 82% | 1223.02 | 660 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0010810 | Biological process | regulation of cell-substrate adhesion |
GO_0043547 | Biological process | positive regulation of GTPase activity |
GO_0010811 | Biological process | positive regulation of cell-substrate adhesion |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005925 | Cellular component | focal adhesion |
GO_0005515 | Molecular function | protein binding |
Gene name | RSU1 |
Protein name | RSU1 protein Ras suppressor protein 1 variant 5 Ras suppressor protein 1 (RSP-1) (Rsu-1) |
Synonyms | RSP1 |
Description | FUNCTION: Potentially plays a role in the Ras signal transduction pathway. Capable of suppressing v-Ras transformation in vitro. |
Accessions | Q32Q10 ENST00000602389.1 [Q15404-2] ENST00000345264.10 [Q15404-1] Q15404 ENST00000377921.7 [Q15404-1] B0YJ73 |